Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Zacks.com on MSN1d
Denali's ALS Study Fails to Meet Primary and Secondary EndpointsDNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II ...
GlobalData on MSN2d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trialThe primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.According ...
Calico, Google's anti-aging subsidiary, has announced disappointing results from its first-ever drug trial. The experimental ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback